---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-115980"
form_type: "8-K"
ticker: "ASMB"
cik: "0001426800"
company_name: "ASSEMBLY BIOSCIENCES, INC."
filed_at: "2026-03-19T23:59:59+00:00"
generated_at: "2026-05-15T09:36:36.610970+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Assembly Biosciences reports 2025 revenue of $72.3M; net loss narrows; licenses HPI program to Gilead

## Summary
- Revenue from Gilead collaboration was $72.3M in 2025 (vs $28.5M in 2024); net loss per share $0.55 (vs $6.69).
- Cash and marketable securities $248.1M as of Dec 31, 2025, projected to fund operations into 2028.
- Licensed helicase-primase inhibitor program (ABI-5366, ABI-1179) to Gilead; received net $35M option fee.
- Gilead declined option on ABI-4334 (HBV capsid modulator); Assembly seeking partner for that program.
- Phase 2 initiation for ABI-6250 (HDV entry inhibitor) anticipated by end of 2026.

## SEC filing metadata
- accession: 0001193125-26-115980
- form_type: 8-K
- ticker: ASMB
- cik: 0001426800
- company_name: ASSEMBLY BIOSCIENCES, INC.
- filed_at: 2026-03-19T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1426800/000119312526115980/0001193125-26-115980-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1426800/000119312526115980/asmb-20260319.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-115980
- JSON: https://secwatch.observer/filing/0001193125-26-115980.json
- Plain text: https://secwatch.observer/filing/0001193125-26-115980.txt

## Key facts
- Earnings Releases
  ASSEMBLY BIOSCIENCES, INC. reported the year ended December 31, 2025 results: revenue $72.3 million, net income Net loss attributable to common stockholders was $6.1 million, EPS $0.55 per basic and diluted share.
  - Period: the year ended December 31, 2025
  - Revenue: $72.3 million
  - Net income: Net loss attributable to common stockholders was $6.1 million
  - EPS: $0.55 per basic and diluted share
  - Result: reported results
  source text: Year-End 2025 Financial Results • Cash, cash equivalents and marketable securities were $248.1 million as of December 31, 2025, compared to $232.6 million as of September 30, 2025, and $112.1 million as of the year ended December 31, 2024. The company’s cash position is projected to fund operations into 2028. • Revenue from collaborative research with Gilead was $72.3 million for the year ended December 31, 2025, compared to $28.5 million in 2024. The increase reflects the increase in collaboration funding. • Research and development expenses were $64.8 million for the year ended December 31, 2025, compared to $55.9 million in 2024. The increase is largely driven by an increase in spending on the HPI program, as both ABI-1179 and ABI-5366 saw significant enrollment in their respective Phase 1b clinical studies during the current year. • General and administrative expenses were $19.6 million for the year ended December 31, 2025, compared to $18.0 million in 2024. The increase was primar
  evidence_url: https://www.sec.gov/Archives/edgar/data/1426800/000119312526115980/0001193125-26-115980-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.